Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04776395 · ClinicalTrials.gov registry record · Phase 2
Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma
A Phase 2 study of Smoldering Plasma Cell Myeloma, sponsored by Emory University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 68
- Enrollment target
- 1
- Study location
NCT04776395 is a Phase 2 study of Smoldering Plasma Cell Myeloma that is actively recruiting participants, run by Emory University. The registered enrollment target is 68 participants, below the 132-participant average among 9 other Smoldering Plasma Cell Myeloma trials with a reported enrollment target (48% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04776395, a Phase 2 study of Smoldering Plasma Cell Myeloma, is actively recruiting participants, sponsored by Emory University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 68 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial studies the effects of iberdomide when given alone or in combination with dexamethasone in treating intermediate or high-risk smoldering multiple myeloma patients. Immunotherapy with iberdomide may induce changes in body's immune system and may interfere with the ability of cancer cells to grow and spread. Dexamethasone is a synthetic steroid (similar to steroid hormones produced naturally in the adrenal gland), and is used with other drugs in the treatment of some types of cancer. Giving iberdomide with dexamethasone my improve time to progression to symptomatic myeloma with improved tolerability.
Conditions Studied
Interventions
- OTHER Quality-of-Life Assessment
- DRUG Dexamethasone
- DRUG Iberdomide Hydrochloride
Study Locations (1)
Georgia
- Emory University Hospital/Winship Cancer Institute - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2021-11-02 |
| Est. Completion | 2029-09-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04776395
The ClinicalTrials.gov registry entry for NCT04776395 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 132-participant average among 9 other Smoldering Plasma Cell Myeloma trials with a reported enrollment target (48% lower). The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Smoldering Plasma Cell Myeloma appearing as the primary indexed condition, and to 3 interventions - of which Quality-of-Life Assessment is the first listed.
NCT04776395 reports 1 study location spanning 1 distinct geographic area - top geographies include Georgia.
Frequently Asked Questions
What is clinical trial NCT04776395 about?
NCT04776395 is a clinical study titled "Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma". This phase II trial studies the effects of iberdomide when given alone or in combination with dexamethasone in treating intermediate or high-risk smoldering multiple myeloma patients. Immunotherapy with iberdomide may induce changes in body's immune system and may interfere with the ability of cance...
What is the current status of trial NCT04776395?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 68 participants. The study started on 2021-11-02. Estimated completion is 2029-09-01.
What conditions does trial NCT04776395 study?
This clinical trial studies the following conditions: Smoldering Plasma Cell Myeloma.
What interventions are being tested in trial NCT04776395?
The interventions under investigation include: Quality-of-Life Assessment (OTHER), Dexamethasone (DRUG), Iberdomide Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT04776395?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04776395 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Smoldering Plasma Cell Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Isatuximab With or Without Lenalidomide in Patients With High Risk Smoldering Multiple Myeloma (ISAMAR)
ACTIVE NOT RECRUITING · Phase 2
-
Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients
ACTIVE NOT RECRUITING · Phase 2
-
Observational Prospective Research Study In Monoclonal Gammopathies leadINg to Myeloma
RECRUITING
-
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
RECRUITING · Phase 3
-
Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma
RECRUITING · NA
-
Quality of Life in Patients With Asymptomatic Monoclonal Gammopathies
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.